ASX ANNOUNCEMENT

CE MARKING OF CELLMID'S MIDKINE ELISA

- **Confirmation that Cellmid's Midkine ELISA is now CE Marked**
- **CE Marking means that the ELISA conforms to European regulations**
- **CE Marking is under the "general in vitro diagnostic" classification**

SYDNEY, 12 October 2011: Cellmid Limited (ASX: CDY) has completed CE (Conformitè Europèene) Marking of its diagnostic midkine ELISA kit (MK ELISA). The Company has registered the device with the Medicines and Healthcare products Regulatory Agency (MHRA), the executive agency of the Department of Health in the United Kingdom, and the GMP manufactured MK ELISA may now carry the CE Marking in accordance with Directive 98/79/EC. The MK ELISA is classified as a general *in vitro* diagnostic device.

CE Marking is an important commercial milestone for Cellmid, as it allows for its MK ELISA to be sold throughout Europe. Early sales are expected primarily from validation studies. Commercial use should follow as the body of evidence continues to grow in support of the usefulness of the test and its contribution to the early diagnosis, prognosis and disease management of cancer.

Earlier this year we reported that Cellmid has completed GMP manufacture of its MK ELISA, which was an important milestone towards the Company's registration to enable European CE marking of the kit. This regulatory step has now been achieved opening up the opportunity for commercial sales.

The MK ELISA is highly accurate in quantifying serum midkine concentrations between 25 and 1000 picogram/mL (dynamic range). This is very important as most healthy adults have around 300 picogram/mL serum midkine levels or less. With the current dynamic range Cellmid's MK ELISA may be used to differentiate between healthy individuals and patients who suffer from cancer.

The commercially produced, GMP compliant and CE marked MK ELISA will be made available to collaboration partners and licensees in addition to its release for commercial sales.

End

Contact:
Maria Halasz, CEO
T +612 9299 0311

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development program is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.

Midkine (MK)

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.